NEW YORK (GenomeWeb) – Illumina and Bristol-Myers Squibb announced after the close of the market Friday that they will collaborate on developing and commercializing companion diagnostics to support BMS' oncology drug pipeline.

The companies plan to develop a diagnostic version of Illumina's TruSight Oncology 500, an assay being developed to target most of the known biomarkers for cancer drugs, including tumor mutation burden and miscrosatellite instability. The panel will run on Illumina's NextSeq 550Dx.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.